Leishmania infantum amastin protein incorporated in distinct adjuvant systems induces protection against visceral leishmaniasis.

[1]  R. Machado-de-Ávila,et al.  Diagnostic evaluation of the amastin protein from Leishmania infantum in canine and human visceral leishmaniasis and immunogenicity in human cells derived from patients and healthy controls. , 2019, Diagnostic microbiology and infectious disease.

[2]  I. Sharifi,et al.  Immunogenicity and protection effects of cationic liposome containing imiquimod adjuvant on leishmaniasis in BALB/c mice , 2019, Iranian journal of basic medical sciences.

[3]  D. Mitra,et al.  Prophylactic interferon-γ and interleukin-17 facilitate parasite clearance in experimental visceral leishmaniasis , 2019, Tropical parasitology.

[4]  Keerti,et al.  Visceral leishmaniasis: An overview of vaccine adjuvants and their applications. , 2019, Vaccine.

[5]  B. Sarkari,et al.  Attenuated Leishmania major Induce a High Level of Protection against Leishmania infantum in BALB/c Mice , 2019, Iranian journal of parasitology.

[6]  F. Gärtner,et al.  Understanding Resistance vs. Susceptibility in Visceral Leishmaniasis Using Mouse Models of Leishmania infantum Infection , 2019, Front. Cell. Infect. Microbiol..

[7]  Pushpanjali,et al.  Visceral leishmaniasis: A novel nuclear envelope protein ‘nucleoporins‐93 (NUP‐93)’ from Leishmania donovani prompts macrophage signaling for T‐cell activation towards host protective immune response , 2019, Cytokine.

[8]  F. Huang,et al.  DNA prime‐protein boost vaccine encoding HLA‐A2, HLA‐A24 and HLA‐DR1 restricted epitopes of CaNA2 against visceral leishmaniasis , 2018, Immunology.

[9]  N. Santarém,et al.  Quantification of Leishmania Parasites in Murine Models of Visceral Infection. , 2019, Methods in molecular biology.

[10]  J. Moreno,et al.  Cellular Markers of Active Disease and Cure in Different Forms of Leishmania infantum-Induced Disease , 2018, Front. Cell. Infect. Microbiol..

[11]  D. Menezes-Souza,et al.  A Leishmania hypothetical protein‐containing liposome‐based formulation is highly immunogenic and induces protection against visceral leishmaniasis , 2018, Cytokine.

[12]  O. Singh,et al.  Visceral leishmaniasis elimination targets in India, strategies for preventing resurgence , 2018, Expert review of anti-infective therapy.

[13]  Jessica A Hinman,et al.  Randomized, controlled, double-blinded field trial to assess Leishmania vaccine effectiveness as immunotherapy for canine leishmaniosis. , 2018, Vaccine.

[14]  J. Greenbaum,et al.  Improved methods for predicting peptide binding affinity to MHC class II molecules , 2018, Immunology.

[15]  B. Singh,et al.  Extracellular release of virulence factor major surface protease via exosomes in Leishmania infantum promastigotes , 2018, Parasites & Vectors.

[16]  D. Menezes-Souza,et al.  Vaccination with a CD4+ and CD8+ T‐cell epitopes‐based recombinant chimeric protein derived from Leishmania infantum proteins confers protective immunity against visceral leishmaniasis , 2018, Translational research : the journal of laboratory and clinical medicine.

[17]  R. Giunchetti,et al.  Therapeutic vaccine of killed Leishmania amazonensis plus saponin reduced parasite burden in dogs naturally infected with Leishmania infantum. , 2018, Veterinary parasitology.

[18]  Leopoldo F M Machado,et al.  New Vaccine Formulations Containing a Modified Version of the Amastigote 2 Antigen and the Non-Virulent Trypanosoma cruzi CL-14 Strain Are Highly Antigenic and Protective against Leishmania infantum Challenge , 2018, Front. Immunol..

[19]  K. Seifert,et al.  Histopathological and immunohistochemical characterisation of hepatic granulomas in Leishmania donovani-infected BALB/c mice: a time-course study , 2018, Parasites & Vectors.

[20]  N. Ali,et al.  Liposomal Elongation Factor-1α Triggers Effector CD4 and CD8 T Cells for Induction of Long-Lasting Protective Immunity against Visceral Leishmaniasis , 2018, Front. Immunol..

[21]  M. O. Rocha,et al.  Identification of immune biomarkers related to disease progression and treatment efficacy in human visceral leishmaniasis. , 2017, Immunobiology.

[22]  S. Sundar,et al.  Chemotherapeutics of visceral leishmaniasis: present and future developments , 2017, Parasitology.

[23]  D. Menezes-Souza,et al.  Selection strategy of phage-displayed immunogens based on an in vitro evaluation of the Th1 response of PBMCs and their potential use as a vaccine against Leishmania infantum infection , 2017, Parasites & Vectors.

[24]  G. Lochnit,et al.  The Eukaryotic Elongation Factor 1 Alpha (eEF1α) from the Parasite Leishmania infantum Is Modified with the Immunomodulatory Substituent Phosphorylcholine (PC) , 2017, Molecules.

[25]  D. Menezes-Souza,et al.  Recombinant small glutamine‐rich tetratricopeptide repeat‐containing protein of Leishmania infantum: Potential vaccine and diagnostic application against visceral leishmaniasis , 2017, Molecular immunology.

[26]  P. Das,et al.  Immuno-informatics based approaches to identify CD8+ T cell epitopes within the Leishmania donovani 3-ectonucleotidase in cured visceral leishmaniasis subjects. , 2017, Microbes and infection.

[27]  D. Bartholomeu,et al.  Epitope mapping of recombinant Leishmania donovani virulence factor A2 (recLdVFA2) and canine leishmaniasis diagnosis using a derived synthetic bi-epitope , 2017, PLoS neglected tropical diseases.

[28]  D. Menezes-Souza,et al.  A recombinant chimeric protein composed of human and mice‐specific CD4+ and CD8+ T‐cell epitopes protects against visceral leishmaniasis , 2017, Parasite immunology.

[29]  C. Müller-Goymann,et al.  Saponin Interactions with Model Membrane Systems – Langmuir Monolayer Studies, Hemolysis and Formation of ISCOMs , 2016, Planta Medica.

[30]  D. Menezes-Souza,et al.  Recent updates and perspectives on approaches for the development of vaccines against visceral leishmaniasis. , 2016, Revista da Sociedade Brasileira de Medicina Tropical.

[31]  Sarman Singh,et al.  Possibilities and challenges for developing a successful vaccine for leishmaniasis , 2016, Parasites & Vectors.

[32]  D. Menezes-Souza,et al.  Prophylactic properties of a Leishmania‐specific hypothetical protein in a murine model of visceral leishmaniasis , 2015, Parasite immunology.

[33]  S. Teixeira,et al.  Amastin Knockdown in Leishmania braziliensis Affects Parasite-Macrophage Interaction and Results in Impaired Viability of Intracellular Amastigotes , 2015, PLoS pathogens.

[34]  M. N. Melo,et al.  Evaluation of adjuvant activity of fractions derived from Agaricus blazei, when in association with the recombinant LiHyp1 protein, to protect against visceral leishmaniasis. , 2015, Experimental parasitology.

[35]  S. Kaur,et al.  Studies on cocktails of 31‐kDa, 36‐kDa and 51‐kDa antigens of Leishmania donovani along with saponin against murine visceral leishmaniasis , 2015, Parasite immunology.

[36]  Adriano Queiroz,et al.  Protective and Pathological Functions of CD8+ T Cells in Leishmania braziliensis Infection , 2014, Infection and Immunity.

[37]  C. Dumas,et al.  An Alba‐domain protein contributes to the stage‐regulated stability of amastin transcripts in Leishmania , 2014, Molecular microbiology.

[38]  R. Nagem,et al.  Antigenicity and Protective Efficacy of a Leishmania Amastigote-specific Protein, Member of the Super-oxygenase Family, against Visceral Leishmaniasis , 2013, PLoS neglected tropical diseases.

[39]  C. Carneiro,et al.  Parasite Burden in Hamsters Infected with Two Different Strains of Leishmania (Leishmania) infantum: “Leishman Donovan Units” versus Real-Time PCR , 2012, PloS one.

[40]  R. Gazzinelli,et al.  Making an anti-amastigote vaccine for visceral leishmaniasis: rational, update and perspectives. , 2012, Current opinion in microbiology.

[41]  U. Lopes,et al.  Peripheral expression of LACK-mRNA induced by intranasal vaccination with PCI-NEO-LACK defines the protection duration against murine visceral leishmaniasis , 2012, Parasitology.

[42]  M. Santoro,et al.  Identification of Proteins in Promastigote and Amastigote-like Leishmania Using an Immunoproteomic Approach , 2012, PLoS neglected tropical diseases.

[43]  M. N. Melo,et al.  Evaluation of parasitological and immunological parameters of Leishmania chagasi infection in BALB/c mice using different doses and routes of inoculation of parasites , 2011, Parasitology Research.

[44]  A. Fett-Neto,et al.  Immunoadjuvant and anti-inflammatory plant saponins: characteristics and biotechnological approaches towards sustainable production. , 2011, Mini reviews in medicinal chemistry.

[45]  Maritsa Margaroni,et al.  Cellular vaccination with bone marrow-derived dendritic cells pulsed with a peptide of Leishmania infantum KMP-11 and CpG oligonucleotides induces protection in a murine model of visceral leishmaniasis. , 2011, Vaccine.

[46]  E. Coelho,et al.  Antigenic extracts of Leishmania braziliensis and Leishmania amazonensis associated with saponin partially protects BALB/c mice against Leishmania chagasi infection by suppressing IL-10 and IL-4 production. , 2010, Memorias do Instituto Oswaldo Cruz.

[47]  Morten Nielsen,et al.  NetCTLpan: pan-specific MHC class I pathway epitope predictions , 2010, Immunogenetics.

[48]  A. Fett-Neto,et al.  Production of Plant Bioactive Triterpenoid Saponins: Elicitation Strategies and Target Genes to Improve Yields , 2010, Molecular biotechnology.

[49]  C. Alonso,et al.  Vaccination with the Leishmania major ribosomal proteins plus CpG oligodeoxynucleotides induces protection against experimental cutaneous leishmaniasis in mice. , 2008, Microbes and infection.

[50]  T. Schumacher,et al.  Conditional MHC class I ligands and peptide exchange technology for the human MHC gene products HLA-A1, -A3, -A11, and -B7 , 2008, Proceedings of the National Academy of Sciences.

[51]  J. M. Requena,et al.  Immunohistological features of visceral leishmaniasis in BALB/c mice , 2006, Parasite immunology.

[52]  H. Nakhasi,et al.  Upregulation of surface proteins in Leishmania donovani isolated from patients of post kala-azar dermal leishmaniasis. , 2006, Microbes and infection.

[53]  S. Reed,et al.  Immunogenicity in dogs of three recombinant antigens (TSA, LeIF and LmSTI1) potential vaccine candidates for canine visceral leishmaniasis. , 2005, Veterinary research.

[54]  M. Bergeron,et al.  Characterization and developmental gene regulation of a large gene family encoding amastin surface proteins in Leishmania spp. , 2005, Molecular and biochemical parasitology.

[55]  James Alexander,et al.  Cysteine peptidases as virulence factors of Leishmania. , 2004, Current opinion in microbiology.

[56]  J. Donelson,et al.  The major surface protease (MSP or GP63) of Leishmania sp. Biosynthesis, regulation of expression, and function. , 2003, Molecular and biochemical parasitology.

[57]  G. Matlashewski,et al.  Immune Responses Induced by the Leishmania (Leishmania) donovani A2 Antigen, but Not by the LACK Antigen, Are Protective against Experimental Leishmania (Leishmania) amazonensis Infection , 2003, Infection and Immunity.

[58]  W. McMaster,et al.  Targeted gene deletion in Leishmania major identifies leishmanolysin (GP63) as a virulence factor. , 2002, Molecular and biochemical parasitology.

[59]  L. Gedamu,et al.  Genomic organization and functional expression of differentially regulated cysteine protease genes of Leishmania donovani complex. , 2002, Gene.

[60]  G. Matlashewski,et al.  Characterization of the A2–A2rel gene cluster in Leishmania donovani: involvement of A2 in visceralization during infection , 2001, Molecular microbiology.

[61]  D Sereno,et al.  A new developmentally regulated gene family in Leishmania amastigotes encoding a homolog of amastin surface proteins. , 2000, Molecular and biochemical parasitology.

[62]  P. Debré,et al.  Interleukin‐10 and interleukin‐4 inhibit intracellular killing of Leishmania infantum and Leishmania major by human macrophages by decreasing nitric oxide generation , 1997, European journal of immunology.

[63]  R. Tesh,et al.  Leishmaniases of the New World: current concepts and implications for future research , 1993, Clinical Microbiology Reviews.

[64]  C. Kensil,et al.  Separation and characterization of saponins with adjuvant activity from Quillaja saponaria Molina cortex. , 1991, Journal of immunology.

[65]  P. Tongaonkar,et al.  A semi‐empirical method for prediction of antigenic determinants on protein antigens , 1990, FEBS letters.

[66]  S. Tannenbaum,et al.  Analysis of nitrate, nitrite, and [15N]nitrate in biological fluids. , 1982, Analytical biochemistry.